
FDA Approves Mounjaro to Lower Heart Attack, Stroke, and Cardiovascular Death Risk
The FDA expanded Mounjaro's label to reduce cardiovascular death, heart attack, and stroke risk in high-risk adults with type 2 diabetes. See who qualifies and what SURPASS-CVOT actually proved.
Read FDA Approves Mounjaro to Lower Heart Attack, Stroke, and Cardiovascular Death Risk







